Girl with suspected autism faces 12-match ban for asking transgender opponent: ‘Are you a man?’
Exclusive: Girl, 17, distraught and is latest case to raise major questions about FA’s failure to ban those born male from women’s game
Related Articles
FDA Grants Fast Track Designation to CUSP06 for Platinum-Resistant Ovarian Cancer
CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.
Highlights of ASH®
Get a synopsis of the top hematology research presented at the latest ASH annual meeting and learn how it can help improve your patient management…
2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward
Experts provide insights on the 2024 FDA approvals in several different fields including solid tumors and more in this list featuring the regulatory decisions.
Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL
Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.
Perioperative Pembrolizumab Wins Canadian Approval for Resectable NSCLC
Health Canada has approved perioperative pembrolizumab for resectable non–small cell lung cancer.
Masterclasses | Society of Gynecologic Oncology
Join us for the SGO 2025 Annual Meeting on Women’s Cancer Masterclasses, crafted to advance your professional development and empower you to provide exceptional and…
Myeloma Rounds Seattle | Leukemia and Lymphoma Society
Format Live, In-Person Event *Pre-registration required Live interactive continuing medical education activity for healthcare professionals in Renton, Seattle, Tacoma, and surrounding areas to discuss multiple myeloma…
First-of-Its-Kind Supportive Oncology Program Offers Unique Training Opportunity for Fellows
The Christie NHS Foundation Trust has created a supportive oncology program to train fellows and offer services for patients living with cancer.
FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD
Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary…
ALK in cancer: from function to therapeutic targeting
Nature Reviews Cancer – ALK genetic alterations drive various malignancies through aberrant tyrosine kinase activation, promoting oncogenic cell growth and survival. Here, Voena et al.…
